Related references
Note: Only part of the references are listed.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer
M. McKernan et al.
BRITISH JOURNAL OF CANCER (2008)
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer
JM Blazeby et al.
EUROPEAN JOURNAL OF CANCER (2004)
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer
CW Vickery et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
